Florida Appeals Court Rules Employers Can Penalize Off-Duty Medical Marijuana Use

Court Holds Medical Marijuana Statute Silent on Employment Protections

The Florida First District Court of Appeal upheld a lower court dismissal, finding no statutory language in Florida's Compassionate Medical Cannabis Act that prohibits employers from penalizing off-duty medical marijuana use. The three-judge panel's opinion centered on statutory construction: because the 2016 law explicitly addresses landlord protections and child custody but remains silent on employment, the court declined to read workplace safeguards into the text.

The case involved a plaintiff terminated after testing positive for THC metabolites despite holding a valid medical marijuana card and consuming cannabis solely during non-working hours. The employer's drug-free workplace policy prohibited all Schedule I controlled substances under federal law. Cannabis remains Schedule I under the federal Controlled Substances Act.

The appellate ruling aligns Florida with the majority of medical marijuana states. Only a handful of jurisdictions—including New York, New Jersey, and Connecticut—have enacted explicit employment protections for off-duty medical cannabis use. Most state medical marijuana laws contain carve-outs preserving employer rights to maintain drug-free workplaces and comply with federal contractor obligations.

900,000 Cardholders Face Continued Employment Vulnerability

Florida's Office of Medical Marijuana Use reports approximately 900,000 active medical marijuana cardholders as of June 2026, all of whom now face confirmed legal exposure to workplace discipline for lawful off-duty use. The state's medical program, operational since 2017, permits physicians to recommend cannabis for qualifying conditions including chronic pain, PTSD, cancer, epilepsy, and glaucoma.

Safety-sensitive industries face particular friction. Federal Department of Transportation regulations prohibit safety-sensitive workers—including commercial drivers, pilots, and pipeline operators—from using Schedule I substances regardless of state law. Florida employers in federally regulated sectors face no new compliance burden. The decision simply confirms existing federal preemption.

For private employers outside DOT oversight, the calculus gets murkier. Companies with federal contracts exceeding $100,000 remain subject to the Drug-Free Workplace Act of 1988, which requires policies prohibiting Schedule I substances. Employers without federal ties may choose to accommodate medical marijuana users but face no state-law obligation to do so after this ruling.

The decision leaves Florida's medical marijuana cardholders in the same legal position as patients in most other medical states: authorized to possess and use cannabis under state law, but unprotected from employment consequences.

Legislative Fix Unlikely Before November Ballot Measure

Florida legislators have repeatedly declined to add employment protections to the state's medical marijuana statute despite advocacy from patient groups, making a statutory fix before the November 2026 adult-use ballot measure highly unlikely. The state legislature adjourned its 2026 regular session in May without addressing workplace protections. No special session is scheduled.

Timing matters. Florida voters will decide on Amendment 3 in November 2026, a citizen-initiated measure that would legalize adult-use cannabis for individuals 21 and older. If the measure passes with the required 60% supermajority, the state would transition from medical-only to full legalization. That transition could complicate efforts to retrofit employment protections into either the existing medical statute or a new adult-use framework.

Advocacy groups including the Florida chapter of NORML have pressed for workplace protections since 2018, arguing that off-duty medical use should receive the same treatment as lawful off-duty alcohol consumption. Those efforts have stalled in committee. The appeals court decision removes any ambiguity that might have pressured lawmakers: the statute says what it says, and courts won't legislate protections into silence.

Testing Protocols and Impairment Thresholds Remain Unresolved

The ruling doesn't address THC testing methodologies or establish impairment standards, leaving employers to navigate the gap between detectability and actual workplace impairment. Standard urinalysis screens detect THC-COOH, a non-psychoactive metabolite that can remain detectable for weeks after use in regular consumers. That metabolite indicates prior use. Not current intoxication.

No Florida statute or regulation defines a per-se impairment threshold for THC in employment contexts. Oral fluid and blood tests offer shorter detection windows and correlate more closely with recent use, but most employers continue to rely on urine screens due to cost and lab infrastructure. The mismatch between detection technology and impairment science creates liability exposure for employers who terminate workers based solely on metabolite presence.

Several states have moved toward impairment-based testing. Montana's 2021 adult-use law prohibits adverse employment action based solely on a positive drug test and requires employers to demonstrate actual impairment. New York's 2021 Marijuana Regulation and Taxation Act bars pre-employment THC testing for most positions and requires employers to prove impairment through observable behavior rather than test results alone. Florida has adopted neither model.

For context on how other states handle this issue, see the CannIntel topic hub on Florida medical marijuana employment rights.

The appellate decision is final unless the plaintiff seeks review by the Florida Supreme Court, an outcome most employment attorneys view as unlikely given the statutory clarity. Employers should review drug-free workplace policies to ensure compliance with federal obligations while considering the operational costs of blanket prohibitions on off-duty medical use. We'll be watching November's adult-use vote and whether any legalization language includes employment protections the medical statute omits.